You must be 18 or older — and of legal age in your province — to enter. All products are sold strictly for laboratory research use only and are not for human or veterinary consumption.
By entering you confirm you are a qualified buyer of research materials and agree to our Terms and Research-Use Policy.
Articles on ipamorelin, the selective ghrelin-receptor agonist studied in growth-hormone research, and on sourcing it in Canada for laboratory use.
The inhibitory half of the growth hormone axis: what somatostatin is, the five receptors it works through, why its three-minute half-life produced octreotide, and why the claim that GHRPs suppress it is not supported.
What each half of the CJC-1295 and ipamorelin pair is, where the synergy argument actually comes from, why no study has tested this combination, and how to verify two peptides in one vial.
Sermorelin and ipamorelin compared: a 29-residue fragment of a human hormone against a designed pentapeptide, their very different regulatory histories, and why no study has tested one against the other.
Growth hormone peptides explained: GHRH analogues vs ghrelin mimetics, how CJC-1295, ipamorelin, tesamorelin and GHRPs compare, and sourcing in Canada.
CJC-1295 vs ipamorelin: a GHRH analogue versus a ghrelin-receptor agonist, DAC vs no DAC, what the human studies found, and sourcing in Canada.